Mehmet Salih AYDIN, Aydemir KOÇARSLAN, Fuat DİLMEÇ, Abdussemet HAZAR, Mustafa GÖZ, Abbas Heval DEMİRKOL

The paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population

To investigate the association between the paraoxonase 1 (PON1) c.163T>A and c.575A>G polymorphisms and coronary artery disease (CAD), and whether specific polymorphisms in the PON1 gene are associated with CAD in the southeastern Turkish population. Many different genetic and clinical factors have been identified as causes or contributors to atherosclerosis. Complex diseases such as CAD, hypertension, and diabetes are usually caused by an individual’s susceptibility to various genes, environmental factors, and the interactions between them. The PON1 enzyme has been implicated in the pathogenesis of atherosclerosis and CAD. Materials and methods: Enrolled in this study were 61 patients with CAD and 103 healthy individuals; their DNA was isolated. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to determine the frequencies of the PON1 gene (NM000446.5, GI: 5444) c.163T>A (Hsp92IIT>A) and c.575A>G (AlwIA>G) polymorphisms in CAD cases. Results: Our data indicated that the body mass index (BMI) (27.5 ± 5.7), low-density lipoprotein (LDL-C) values (127.0 ± 45.8), and frequencies of diabetes (13.0) and hypertension (35.0) were significantly higher in CAD patients than in the control subjects (25.9 ± 4.1; 105.6 ± 26.3; 2.0; and 19.0, respectively) (P < 0.05). No significant differences were observed in the frequencies of the c.163T>A and c.575A>G genotypes of the PON1 gene in CAD patients compared to healthy individuals (P > 0.05). Conclusion: The PON1 gene c.163T>A and c.575A>G polymorphisms did not represent an important risk factor for this disease in the southeastern Turkish population.

Anahtar Kelimeler:

Key words: PON1 gene, polymorphism, coronary artery disease, PCR, RFLP

The paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population

Keywords:

Key words: PON1 gene, polymorphism, coronary artery disease, PCR, RFLP,

PDF

___

Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62: 36-44.
Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998; 9: 319-24.
Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 2009; 130: 361-8.
Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ et al. Human PON2-gene at 7q 21.3: cloning, multiple mRNA forms, and missense polymorphism in the coding sequence. Gene 1998; 213: 149-57.
Beltowski J, Wojcicka G, Marciniak A. Species and substrate- specifi c stimulation of human plasma paraoxonase1 (PON1) activity by high chloride concentration. Acta Biochimica Polonica 2002; 49: 927-36.
Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
Ellsworth DL, Sholinsky P, Jaquish C, Fabsitz RR, Manolio TA. Coronary heart disease: at the interface of molecular genetics and preventive medicine. American Journal of Preventive Medicine 1999; 16: 122-33.
Hong SH, Song J, Min WK, Kim JQ. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 2001; 34: 475-81.
Allebrandt KV, Souza RL, Chautard-Freire-Maia EA. Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol Appl Pharmacol 2002; 180: 151-56.
Agrawal S, Tripathi G, Prajnya R, Sinha N, Gilmour A, Bush L et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009; 63: 335-44.
Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G et al. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002; 32: 9-15.
Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Th romb Vasc Biol 2001; 21: 1451-7.
Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G et al. Mutations in the human paraoxonase gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 1999; 9: 755-61.
Mendonça MI, Dos Reis RP, Freitas AI, Sousa AC, Pereira A, Faria P et al. Gene-gene interaction aff ects coronary artery disease risk. Rev Port Cardiol 2009; 28: 397-415.
Th yagarajan B, Jacobs DR Jr, Carr JJ, Alozie O, Steff es MW, Kailash P et al. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2008; 54: 738-46.
Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Annichino- Bizzacchi JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004; 94: 7.
Özkök E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit 2008; 14: 536-42.
Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N et al. Th e relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars 2009; 37: 473-8.
Kaman D, Ilhan N, Metin K, Akbulut M, Ustündağ B. A preliminary study of human paraoxonase and PON 1 L/M55- PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct 2009; 27: 88-92.
Chi DS, Ling WH, Ma J, Xia M, Hou MJ, Wang Q et al. Relationship between paraoxonase 1 55 Met/Leu, paraoxonase 148 Ala/Gly genetic polymorphisms and coronary artery disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23: 289
Aynacioglu AS, Kepekci Y. Th e human paraoxonase Gln- Argl92 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 2000; 74: 33-7.
Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P et al. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001; 79: 449-58.
Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. Th e role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010; 61: 157-65.
Balcerzyk A, Zak I, Krauze J. Protective eff ect of R allele of PON1 gene on the coronary artery disease in the presence of specifi c genetic background. Dis Markers 2008; 24: 81-8.
Mohamed RH, Mohamed RH, Karam RA, Abd El-Aziz TA. Th e relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 2010; : 553-58.
Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006; 47: 515-20.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
Rea IM, McKeown PP, McMaster D, Young IS, Patterson C, Savage MJ et al. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol 2004; 39: 629-35.
Sentí M, Tomás M, Vila J, Marrugat J, Elosua R, Sala J et al. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Atherosclerosis 2001; 156: 443-49.
Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors infl uencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004; 39: 59-66.
Kuremoto K, Watanabe Y, Ohmura H, Shimada K, Mokuno H, Daida H. R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. J Atheroscler Th romb 2003; : 85-92.
Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, Tanck MW et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One 2009; : e6809.